Industry reports
Editor highlights

Publication dates

All regions

Prostate Cancer Research Reports, April 2014

You might be interested in: cancer, medical equipment, therapeutics, more »


 

1-20 of about 5 900 reports for Prostate Cancer
InterGenetics Incorporated - Strategic SWOT Analysis Review

InterGenetics Incorporated - Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • April 2014
  • by Global Data

... Risk. The comapny also has a range of research pipeline of predictive tests for other cancers such as ovarian, colon, and prostate cancer. Intergenetics is headquartered in oklahoma, the us ...

HealthLinx Limited (Symbol:HTX) SWOT Analysis, Strategy, Revenues and Profits

HealthLinx Limited (Symbol:HTX) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • April 2014
  • by Global Data

... Depletion and recovery technology for serum or plasma and other biological fluids. The company offers products for the treatment of colorectal cancer and prostate cancer. It holds for vascular permeability ...

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014

  • $ 2 500
  • Industry report
  • April 2014
  • by Global Data

... Provides briefing pertaining to the number of trials for the key drugs for treating metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer. This report is built using data ...

Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014

Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014

  • $ 2 500
  • Industry report
  • April 2014
  • by Global Data

... To the clinical trials on metastatic prostate cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...

Active Biotech AB (ACTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Active Biotech AB (ACTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • March 2014
  • by Global Data

... Key products in development include laquinimod, for the treatment of multiple sclerosis; tasquinimod for the treatment of prostate cancer; anyara for the treatment of renal cell cancer. Laquinimod ...

Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014

Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014

  • $ 2 500
  • Industry report
  • March 2014
  • by Global Data

... Information and data relating to the clinical trials on hormone-sensitive prostate cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ...

Analytical Tool - Prostate Cancer

Analytical Tool - Prostate Cancer

  • $ 4 650
  • Industry report
  • March 2014
  • by Bioseeker

... Analytical tool - prostate cancer "analytical tool - prostate cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostate cancer r ...

Prostate Cancer Drug Pathway Analyzer 2014

Prostate Cancer Drug Pathway Analyzer 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

... Specifications3. Compare - you can overlay any pathways with each other and do a comparative analysisyou can interactively analyze any prostate cancer drug-pathway relationship by using up to four ...

Prostate Cancer Drug Pipeline Update 2014

Prostate Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

... To alternatives. Establishing the optimal timing of antihormonal therapy will provide the key to market growth.There are today 349 companies plus partners developing 414 drugs targeting prostate cancer ...

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014

  • $ 2 500
  • Industry report
  • March 2014
  • by Global Data

... Countries: proportion of hormone refractory (castration resistant, androgen-independent) prostate cancer to oncology clinical trials 17clinical trials by phase in g7 countries 18clinical trials in g7 ...


» Read our Company Profiles

2 Companies for Prostate Cancer

Management Strategies

United States

Johnson and Johnson

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.